In addition, a previous study has highlighted FGFR2 signaling as a mechanism of acquired resistance to EGFR TKIs, and suggested that treatment of NSCLC patients with combinations of EGFR and FGFR specific TKIs may be a strategy to enhance efficacy of single EGFR inhibitors [23]. The gene discussed is FGFR2; the disease is non-small cell lung carcinoma.